Skip to main content

Table 1 Vaccines characteristics and outcomes (randomized clinical trials)

From: Vaccination and screening programs: harmonizing prevention strategies for HPV-related diseases

Name ™ GARDASIL CERVARIX
   L1 VLP antigens HPV 6 (20 mg) HPV 16 (20 mg)
  HPV 11 (40 mg) HPV 18 (20 mg)
  HPV 16 (40 mg)  
  HPV 18 (20 mg)  
   Expression system Saccharomyces cerevisiae Baculovirus
   Adjuvant HAAS
aluminium hydroxyphosphate sulphate
ASO4
aluminium hydroxide plus
3-deacylated monophosphoryl lipid A
   Dose schedule 0, 2 and 6 months 0, 1 and 6 months
PHASE III RANDOMIZED TRIALS   
   Name FUTURE I (13) and II (14)
Females United to Unilaterally
Reduce Endo/Ectocervical Disease
PATRICIA (16)
PApilloma TRIal against Cancer
In young Adults
   Years of recruitment 2002–2003 2004–2005
   Age of recruited subjects 16–26 15–25
   Enrolled women 20,583 18,644
   No. of sexual partners ≤4 ≤6
   Random comparator Placebo
(225 or 450 μg of aluminum)
Hepatitis A vaccine
IMMUNOLOGIC RESPONSE   
   Seroconversion ~100% ~100%
   Serologic detection method cLIA * binding ELISA
   Immunogenicity Established Established
   Immune memory at 6 (5?) yrs Established Not reported
CLINICAL RESPONSE   
   Follow-up 3 years 15 months (interim analysis)
   Prophylactic efficacy   
HPV 16 CIN2/3+ Established Established
HPV 18 CIN2/3+ Established Positive trend
HPV 16/18 VIN3 Established Not reported
HPV 16/18 VaIN3 Established Not reported
6/11 genital warts Established Not a target
   Tolerability Well tolerated Well tolerated
   Safety at 6 yrs Established Established
   Therapeutic efficacy None None
  1. * competitive Luminex-based immune-assays